98 related articles for article (PubMed ID: 26960957)
1. History of ABVD alters the number of oocytes vitrified after in vitro maturation in fertility preservation candidates.
Sonigo C; Seroka A; Cédrin-Durnerin I; Sermondade N; Sifer C; Grynberg M
Future Oncol; 2016 Jul; 12(14):1713-9. PubMed ID: 26960957
[TBL] [Abstract][Full Text] [Related]
2. Letter in reply to "Fertility preservation before an ABVD protocol: no new evidence to support changing the recommendations".
Sonigo C; Sermondade N; Grynberg M
Future Oncol; 2017 Mar; 13(7):591-592. PubMed ID: 27928934
[No Abstract] [Full Text] [Related]
3. Fertility preservation before an ABVD protocol: no new evidence to support changing the recommendations.
Poirot C; Dhedin N; Brice P
Future Oncol; 2017 Mar; 13(7):589-590. PubMed ID: 27921440
[No Abstract] [Full Text] [Related]
4. Impact of ABVD chemotherapy on ovarian reserve after fertility preservation in reproductive-aged women with Hodgkin lymphoma.
Policiano C; Subirá J; Aguilar A; Monzó S; Iniesta I; Rubio Rubio JM
J Assist Reprod Genet; 2020 Jul; 37(7):1755-1761. PubMed ID: 32488563
[TBL] [Abstract][Full Text] [Related]
5. Cryopreservation of in vitro matured oocytes in addition to ovarian tissue freezing for fertility preservation in paediatric female cancer patients before and after cancer therapy.
Abir R; Ben-Aharon I; Garor R; Yaniv I; Ash S; Stemmer SM; Ben-Haroush A; Freud E; Kravarusic D; Sapir O; Fisch B
Hum Reprod; 2016 Apr; 31(4):750-62. PubMed ID: 26848188
[TBL] [Abstract][Full Text] [Related]
6. Hodgkin lymphoma and female fertility: a multicenter study in women treated with doxorubicin, bleomycin, vinblastine, and dacarbazine.
Machet A; Poudou C; Tomowiak C; Gastinne T; Gardembas M; Systchenko T; Moya N; Debiais C; Levy A; Gruchet C; Sabirou F; Noel S; Bouyer S; Leleu X; Delwail V; Guidez S
Blood Adv; 2023 Aug; 7(15):3978-3983. PubMed ID: 36129842
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal study of AMH variations in 122 Adolescents and Young Adults (AYA) and non-AYA lymphoma patients to evaluate the chemo-induced ovarian toxicity to further personalise fertility preservation counselling.
Decanter C; Delepine J; Behal H; Manier S; Bruno B; Barbatti M; Robin C; Labreuche J; Morschhauser F; Pigny P
Hum Reprod; 2021 Sep; 36(10):2743-2752. PubMed ID: 34417822
[TBL] [Abstract][Full Text] [Related]
8. Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial.
Iannitto E; Minardi V; Gobbi PG; Calvaruso G; Tripodo C; Marcheselli L; Luminari S; Merli F; Baldini L; Stelitano C; Callea V; Petrini M; Angrilli F; Quarta G; Vallisa D; Molica S; Liardo E; Polimeno G; Brugiatelli M; Federico M
Clin Lymphoma Myeloma; 2009 Apr; 9(2):138-44. PubMed ID: 19406724
[TBL] [Abstract][Full Text] [Related]
9. Similar in vitro maturation rates of oocytes retrieved during the follicular or luteal phase offer flexible options for urgent fertility preservation in breast cancer patients.
Grynberg M; Poulain M; le Parco S; Sifer C; Fanchin R; Frydman N
Hum Reprod; 2016 Mar; 31(3):623-9. PubMed ID: 26759139
[TBL] [Abstract][Full Text] [Related]
10. Fatal pneumocystis jiroveci pneumonia in ABVD-treated Hodgkin lymphoma patients.
Kalin M; Kristinsson SY; Cherif H; Lebbad M; Björkholm M
Ann Hematol; 2010 May; 89(5):523-5. PubMed ID: 19768459
[No Abstract] [Full Text] [Related]
11. [Hodgkin lymphoma--ABVD regimen].
Nagai H
Nihon Rinsho; 2015 Feb; 73 Suppl 2():642-5. PubMed ID: 25831839
[No Abstract] [Full Text] [Related]
12. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
Jalali A; Ha FJ; Chong G; Grigg A; Mckendrick J; Schwarer AP; Doig R; Hamid A; Hawkes EA
Ann Hematol; 2016 Apr; 95(5):809-16. PubMed ID: 26878861
[TBL] [Abstract][Full Text] [Related]
13. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
Viviani S; Zinzani PL; Rambaldi A; Brusamolino E; Levis A; Bonfante V; Vitolo U; Pulsoni A; Liberati AM; Specchia G; Valagussa P; Rossi A; Zaja F; Pogliani EM; Pregno P; Gotti M; Gallamini A; Rota Scalabrini D; Bonadonna G; Gianni AM; ; ;
N Engl J Med; 2011 Jul; 365(3):203-12. PubMed ID: 21774708
[TBL] [Abstract][Full Text] [Related]
14. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
Behringer K; Goergen H; Hitz F; Zijlstra JM; Greil R; Markova J; Sasse S; Fuchs M; Topp MS; Soekler M; Mathas S; Meissner J; Wilhelm M; Koch P; Lindemann HW; Schalk E; Semrau R; Kriz J; Vieler T; Bentz M; Lange E; Mahlberg R; Hassler A; Vogelhuber M; Hahn D; Mezger J; Krause SW; Skoetz N; Böll B; von Tresckow B; Diehl V; Hallek M; Borchmann P; Stein H; Eich H; Engert A; ; ;
Lancet; 2015 Apr; 385(9976):1418-27. PubMed ID: 25539730
[TBL] [Abstract][Full Text] [Related]
15. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly.
Stamatoullas A; Brice P; Bouabdallah R; Mareschal S; Camus V; Rahal I; Franchi P; Lanic H; Tilly H
Br J Haematol; 2015 Jul; 170(2):179-84. PubMed ID: 25891777
[TBL] [Abstract][Full Text] [Related]
16. Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.
Hoskin PJ; Lowry L; Horwich A; Jack A; Mead B; Hancock BW; Smith P; Qian W; Patrick P; Popova B; Pettitt A; Cunningham D; Pettengell R; Sweetenham J; Linch D; Johnson PW
J Clin Oncol; 2009 Nov; 27(32):5390-6. PubMed ID: 19738111
[TBL] [Abstract][Full Text] [Related]
17. Second hematologic malignancies after ABVD: Two case reports and a retrospective study of 183 Hodgkin lymphoma patients.
Leong C; Ngeow J; Tan I; Quek R; Tao M; Loh Y; Tan HC; Lim ST
Acta Oncol; 2010; 49(2):257-9. PubMed ID: 19839917
[No Abstract] [Full Text] [Related]
18. Low incidence of long-term respiratory impairment in Hodgkin lymphoma survivors.
Avivi I; Hardak E; Shaham B; Igla M; Rowe JM; Dann EJ
Ann Hematol; 2012 Feb; 91(2):215-21. PubMed ID: 21603918
[TBL] [Abstract][Full Text] [Related]
19. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
Duggan DB; Petroni GR; Johnson JL; Glick JH; Fisher RI; Connors JM; Canellos GP; Peterson BA
J Clin Oncol; 2003 Feb; 21(4):607-14. PubMed ID: 12586796
[TBL] [Abstract][Full Text] [Related]
20. Reduced versus full doses of irradiation after 3 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine in early stage Hodgkin lymphomas: results of a randomized trial.
Arakelyan N; Jais JP; Delwail V; Brière J; Moles-Moreau MP; Sénécal D; Berthou C; Desablens B; Colonna P; Andrieu JM;
Cancer; 2010 Sep; 116(17):4054-62. PubMed ID: 20564152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
